Učitavanje...

The clinical utility of aflibercept for diabetic macular edema

The treatment of center-involving diabetic macular edema (DME) has improved because of the proven efficacy of drugs that inhibit the effects of vascular endothelial growth factor (VEGF). The newest anti-VEGF drug, aflibercept, has recently been approved by the United States Food and Drug Administrat...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Diabetes Metab Syndr Obes
Glavni autor: Stewart, Michael W
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2015
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4583120/
https://ncbi.nlm.nih.gov/pubmed/26425104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S72792
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!